Xiaolong Yan

18PUBLICATIONS
41CO-AUTHORS
BiomaterialsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical infection agents (incl. prions)Medical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 17, 2026
Alternating Shear Force of Respiration Regulates Cell Interactions of Fibroblasts and Macrophages to Promote Soft Tissue Integration of Chest Wall Polyetheretherketone Implants.

|Apr 15, 2026
Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.

Zhiyuan Gao, Zhengxuan Li, Xin Yao

|Mar 02, 2026
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.

Yushang Yang, Xiaolong Yan, Hongjing Jiang

|Feb 02, 2026
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.

Fan Zhang, Zhendong Zheng, Hongmei Zhang

|Dec 17, 2025
Causal Relationship Between Gut Microbiota and Pressure Ulcers: A Two-Sample Bidirectional Mendelian Randomisation Study.

Pei Luo, Liqing Jiang, Hongmei Chen

|Dec 10, 2025
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.

Yizhang Li, Jialing Jiang, Xin Yao

Pageof 3

Frequent Collaborators

3 joint publications

Yuanyong Wang

2 joint publications

Jing Han

2 joint publications

Xiaofei Li

2 joint publications

Zhaoyang Wang